Ellen M. Basu

2.8k total citations
58 papers, 772 citations indexed

About

Ellen M. Basu is a scholar working on Neurology, Oncology and Cancer Research. According to data from OpenAlex, Ellen M. Basu has authored 58 papers receiving a total of 772 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Neurology, 20 papers in Oncology and 20 papers in Cancer Research. Recurrent topics in Ellen M. Basu's work include Neuroblastoma Research and Treatments (55 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Lung Cancer Research Studies (20 papers). Ellen M. Basu is often cited by papers focused on Neuroblastoma Research and Treatments (55 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Lung Cancer Research Studies (20 papers). Ellen M. Basu collaborates with scholars based in United States, United Kingdom and Switzerland. Ellen M. Basu's co-authors include Shakeel Modak, Brian H. Kushner, Stephen S. Roberts, Nai‐Kong V. Cheung, Irene Y. Cheung, Kim Kramer, Michael P. LaQuaglia, Audrey Mauguen, Govind Ragupathi and Irina Ostrovnaya and has published in prestigious journals such as Journal of Clinical Oncology, PEDIATRICS and Cancer.

In The Last Decade

Ellen M. Basu

52 papers receiving 766 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellen M. Basu United States 15 513 310 268 175 140 58 772
BH Kushner United States 10 381 0.7× 267 0.9× 155 0.6× 109 0.6× 142 1.0× 14 608
Valeria Smith United States 7 393 0.8× 252 0.8× 117 0.4× 153 0.9× 51 0.4× 18 531
R. Handgretinger Germany 15 286 0.6× 228 0.7× 222 0.8× 75 0.4× 226 1.6× 33 718
T Philip France 14 248 0.5× 206 0.7× 265 1.0× 101 0.6× 165 1.2× 46 692
Scott C. Bresler United States 10 322 0.6× 290 0.9× 237 0.9× 181 1.0× 38 0.3× 34 603
M. M. Uttenreuther-Fischer Germany 13 231 0.5× 201 0.6× 198 0.7× 67 0.4× 143 1.0× 24 542
MY Mapara Germany 10 177 0.3× 150 0.5× 443 1.7× 158 0.9× 161 1.1× 11 795
J.P. Vannier France 10 190 0.4× 203 0.7× 185 0.7× 60 0.3× 69 0.5× 26 659
Jacques Vargaftig France 12 188 0.4× 309 1.0× 174 0.6× 98 0.6× 208 1.5× 23 887
Gregor Schulz Germany 14 238 0.5× 272 0.9× 365 1.4× 72 0.4× 195 1.4× 19 792

Countries citing papers authored by Ellen M. Basu

Since Specialization
Citations

This map shows the geographic impact of Ellen M. Basu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen M. Basu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen M. Basu more than expected).

Fields of papers citing papers by Ellen M. Basu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen M. Basu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen M. Basu. The network helps show where Ellen M. Basu may publish in the future.

Co-authorship network of co-authors of Ellen M. Basu

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen M. Basu. A scholar is included among the top collaborators of Ellen M. Basu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen M. Basu. Ellen M. Basu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kushner, Brian H., Shakeel Modak, Audrey Mauguen, et al.. (2025). A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission. Clinical Cancer Research. 31(10). 1877–1884. 1 indexed citations
2.
Desai, Ami V., Amy E. Armstrong, Cornelis M. van Tilburg, et al.. (2025). Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. European Journal of Cancer. 220. 115308–115308. 1 indexed citations
3.
Pandit‐Taskar, Neeta, Ellen M. Basu, Ali Pirasteh, et al.. (2025). Lesion Analysis of 18F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma. Journal of Nuclear Medicine. 66(10). 1568–1574.
4.
Jackson, Christina, Shakeel Modak, Michael P. LaQuaglia, et al.. (2024). Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results from a Prospective Clinical Trial. International Journal of Radiation Oncology*Biology*Physics. 120(2). S49–S49.
5.
Kushner, Brian H., Audrey Mauguen, Ellen M. Basu, et al.. (2024). N9: Pilot study of novel shortened induction for high-risk neuroblastoma.. Journal of Clinical Oncology. 42(16_suppl). 10052–10052.
6.
7.
Gutman, David A., Andrei I. Holodny, Shakeel Modak, et al.. (2024). Evolutionary Strategies AI Addresses Multiple Technical Challenges in Deep Learning Deployment: Proof-of-Principle Demonstration for Neuroblastoma Brain Metastasis Detection. Journal of Imaging Informatics in Medicine. 37(6). 2920–2930. 1 indexed citations
8.
Pandit‐Taskar, Neeta, et al.. (2024). Safety observations in neuroblastoma patients undergoing 18F-mFBG PET. Nuclear Medicine Communications. 46(3). 245–247. 2 indexed citations
9.
Tringale, Kathryn R., Suzanne L. Wolden, Matthias A. Karajannis, et al.. (2023). Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma. Journal of Neuro-Oncology. 162(1). 69–78. 6 indexed citations
10.
Kushner, Brian H., Shakeel Modak, Michael P. LaQuaglia, et al.. (2023). Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy.. Journal of Clinical Oncology. 41(16_suppl). 10037–10037. 1 indexed citations
11.
Kushner, Brian H., Shakeel Modak, Ellen M. Basu, et al.. (2021). Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN‐amplified neuroblastoma. Pediatric Blood & Cancer. 68(10). e29265–e29265. 8 indexed citations
12.
Mathias, Melissa, Michael V. Ortiz, Kay See Tan, et al.. (2019). Local Anesthesia With General Anesthesia for Pediatric Bone Marrow Procedures. PEDIATRICS. 144(2). 3 indexed citations
13.
Casey, Dana L., Brian H. Kushner, Nai‐Kong V. Cheung, et al.. (2019). Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial. International Journal of Radiation Oncology*Biology*Physics. 104(2). 409–414. 14 indexed citations
14.
Modak, Shakeel, Jean-Benoît Le Luduec, Irene Y. Cheung, et al.. (2018). Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. OncoImmunology. 7(8). e1461305–e1461305. 70 indexed citations
15.
Cheung, Irene Y., Brian H. Kushner, Shakeel Modak, et al.. (2017). Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. OncoImmunology. 6(11). e1358331–e1358331. 28 indexed citations
16.
Modak, Shakeel, Brian H. Kushner, Ellen M. Basu, Stephen S. Roberts, & Nai‐Kong V. Cheung. (2017). Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. Pediatric Blood & Cancer. 64(8). 35 indexed citations
17.
Lim, Irene Isabel P., Debra A. Goldman, Benjamin A. Farber, et al.. (2016). Image-defined risk factors for nephrectomy in patients undergoing neuroblastoma resection. Journal of Pediatric Surgery. 51(6). 975–980. 14 indexed citations
18.
Murphy, Jennifer, Irene Isabel P. Lim, Benjamin A. Farber, et al.. (2015). Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass. Journal of Pediatric Surgery. 51(2). 285–288. 9 indexed citations
19.
Kushner, Brian H., Shakeel Modak, Kim Kramer, et al.. (2012). Ifosfamide, carboplatin, and etoposide for neuroblastoma. Cancer. 119(3). 665–671. 35 indexed citations
20.
Kushner, Brian H., Shakeel Modak, Kim Kramer, et al.. (2012). 5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma. Bone Marrow Transplantation. 48(5). 642–645. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by BH Kushner Breakdown of academic impact, for papers by Valeria Smith Breakdown of academic impact, for papers by R. Handgretinger Breakdown of academic impact, for papers by T Philip Breakdown of academic impact, for papers by Scott C. Bresler Breakdown of academic impact, for papers by M. M. Uttenreuther-Fischer Breakdown of academic impact, for papers by MY Mapara Breakdown of academic impact, for papers by J.P. Vannier Breakdown of academic impact, for papers by Jacques Vargaftig Breakdown of academic impact, for papers by Gregor Schulz
Rankless by CCL
2026